Search results for "obstetrics and gynecology"

showing 10 items of 1542 documents

Laparoscopic Radical Hysterectomy After Concomitant Chemoradiation in Locally Advanced Cervical Cancer: A Prospective Phase II Study

2015

Abstract Study Objective To assess the feasibility of total robotic radical surgery (TRRS) in patients with locally advanced cervical cancer (LACC) who receive chemoradiation therapy (CT/RT). Design A prospective (preplanned) study of a nonrandomized controlled trial (Canadian Task Force classification level 2). Setting Catholic University of the Sacred Hearth, Rome, Italy. Patients Between September 2013 and January 2016, a total of 40 patients with LACC (Federation Internationale de Gynecologie et d'Obstetrique stage IB2–III) were enrolled in the study. Interventions Robotic radical hysterectomy (RRH) plus pelvic and/or aortic lymphadenectomy was attempted within 6 weeks after CT/RT. The …

AdultUterine Cervical Neoplasmmedicine.medical_specialtymedicine.medical_treatmentUterine Cervical NeoplasmsHysterectomyPostoperative ComplicationsmedicineRadical hysterectomyHumansProspective StudiesCervical cancer; Laparoscopy; Neoadiuvant chemoradiation; Radical hysterectomy; Adult; Aged; Carcinoma; Squamous Cell; Chemoradiotherapy; Adjuvant; Cisplatin; Feasibility Studies; Female; Humans; Italy; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence; Local; Postoperative Complications; Prospective Studies; Uterine Cervical Neoplasms; Hysterectomy; Laparoscopy; Lymph Node ExcisionRadical surgeryRadical HysterectomyProspective cohort studyNeoadjuvant therapyAgedCervical cancerHysterectomybusiness.industryMedicine (all)Obstetrics and GynecologyLaparoscopic Radical HysterectomyPerioperativeChemoradiotherapy AdjuvantMiddle Agedmedicine.diseaseNeoadjuvant TherapySurgeryFeasibility StudieProspective StudieSettore MED/40 - GINECOLOGIA E OSTETRICIAItalyCervical cancerNeoadiuvant chemoradiationCarcinoma Squamous CellFeasibility StudiesLymph Node ExcisionLymphadenectomyFemaleLaparoscopyPostoperative ComplicationCisplatinNeoplasm Recurrence LocalbusinessHuman
researchProduct

Vesico-uterine fistula treated by amenorrhoea induced with contraceptive steroids. Two case reports.

1980

2 case reports of women with vesico-uterine fistulae who were successfully treated by inducing amenorrhea by the continuous administration of an estrogen-progestogen compound for 6 months are presented. Ortho-Novum 1/50 was used. The amenorrheic condition induced by continuous ingestion of an oral contraceptive agent allowed the fistula time to heal since fistulae rarely close spontaneously because of fluids flowing fhrough them inhibiting the healing process. This method of management should be tried before surgery the generally recommended treatment.

AdultUterine Diseasesmedicine.medical_specialtyFistulabusiness.industryUrinary Bladder FistulaResearch methodologyFistulaObstetrics and GynecologyUterine Fistulamedicine.diseaseOral contraceptive agentSurgeryContraceptives Oral CombinedFamily planningmedicineHumansAmenorrheaFemalemedicine.symptombusinessAmenorrheaContraceptives OralBritish journal of obstetrics and gynaecology
researchProduct

Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in vitro: implications for treatment of ovarian hypersti…

2013

Objective To ascertain whether vascular endothelial growth factor (VEGF) secretion by luteinized granulosa cells (GCs) is modulated by the dopaminergic system in a dose-dependent fashion and how this is related to the differential efficacy of dopamine receptor 2 (D2)-agonists (D2-ag) in preventing ovarian hyperstimulation syndrome (OHSS). Design The relationship between the dopaminergic system and VEGF secretion in luteinized GCs was evaluated. Archived human ovaries were immunostained to characterize D2 expression. Setting University affiliated infertility center. Patient(s) Premenopausal women and egg donors. Intervention(s) Luteinized GCs were cultured with the D2-ag cabergoline. Human o…

AdultVascular Endothelial Growth Factor Aendocrine systemmedicine.medical_specialtyOvarian hyperstimulation syndromePilot ProjectsLuteal phaseBiologyOvarian Hyperstimulation Syndromechemistry.chemical_compoundCabergolineInternal medicinemedicineHumansSecretionCells CulturedGranulosa CellsReceptors Dopamine D2OvaryDopaminergicObstetrics and GynecologyMiddle Agedmedicine.diseaseVascular endothelial growth factorTreatment OutcomeEndocrinologyReproductive MedicinechemistryDopamine receptorDopamine AgonistsImmunohistochemistryFemalesense organsmedicine.drugFertility and Sterility
researchProduct

MicroRNA expression profile in endometriosis: its relation to angiogenesis and fibrinolytic factors

2014

Study question Could an aberrant microRNA (miRNA) expression profile be responsible for the changes in the angiogenic and fibrinolytic states observed in endometriotic lesions? Summary answer This study revealed characteristic miRNA expression profiles associated with endometriosis in endometrial tissue and endometriotic lesions from the same patient and their correlation with the most important angiogenic and fibrinolytic factors. WHAT IS ALREADY KNOWN?: An important role for dysregulated miRNA expression in the pathogenesis of endometriosis is well documented. However, to the best of our knowledge, there are no reports of the relationship between angiogenic and fibrinolytic factors and mi…

AdultVascular Endothelial Growth Factor Amedicine.medical_specialtyAngiogenesisEndometriosisEndometriosisEndometriumThrombospondin 1EndometriumYoung Adultchemistry.chemical_compoundInternal medicinePlasminogen Activator Inhibitor 1microRNAmedicineHumansNeovascularization Pathologicbusiness.industryRehabilitationObstetrics and GynecologyMicroRNA Expression ProfileMiddle Agedmedicine.diseaseUrokinase-Type Plasminogen ActivatorVascular endothelial growth factorMicroRNAsVascular endothelial growth factor AEndocrinologymedicine.anatomical_structureReproductive MedicinechemistryCase-Control StudiesCancer researchFemalebusinessFibrinolytic agentHuman Reproduction
researchProduct

A first-in-human study of PDC31 (prostaglandin F2  receptor inhibitor) in primary dysmenorrhea

2014

What is the safe and pharmacodynamically active dose range for PDC31 (prostaglandin F2α receptor inhibitor) in patients with primary dysmenorrhea (PD)?The 1 mg/kg/h dose of PDC31 appears to be safe and potentially effective in reducing intrauterine pressure (IUP) and pain associated with excessive uterine contractility when given as a 3-h infusion in patients with PD.PDC31 has previously been shown to reduce the duration and strength of PGF2α-induced contractions in human uterine myometrial strip models and to delay delivery in animal models of preterm labor.This was a prospective, multi-center, dose-escalating first-in-human Phase I study conducted from March 2011 to June 2012. A total of …

AdultVisual analogue scaleUterusPlaceboDrug Administration ScheduleUterine contractionYoung AdultDysmenorrheaPharmacokineticsInfusion ProceduremedicineHumansProspective StudiesAdverse effectDose-Response Relationship Drugbusiness.industryRehabilitationObstetrics and GynecologyTreatment Outcomemedicine.anatomical_structureReproductive MedicineAnesthesiaPharmacodynamicsFemalemedicine.symptomPeptidesbusinessHuman Reproduction
researchProduct

Myofibroblasts Are Evidence of Chronic Tissue Microtrauma at the Endometrial-Myometrial Junctional Zone in Uteri With Adenomyosis.

2017

Background Adenomyosis (AM) uteri exhibit hyperperistalsis. The latter causes a chronic tissue trauma at the endometrial-myometrial junctional zone (EMJZ). Upon tissue trauma, microdehiscences in the myometrium facilitate the translocation of basal endometrial fragments into the myometrium. There, a metaplasia (mediated by transforming growth factor β1 [TGFβ1] and connective tissue growth factor [CTGF]) occurs and AM lesions develop. The abundance of myofibroblasts in a tissue hallmarks metaplasia and points to a tissue microtrauma. Materials and methods To study if myofibroblasts-as an evidence of tissue microtrauma-are more abundant at EMJZ in AM-uteri, a case-control experimental study w…

Adultadenomyosis pathogenesiPathologymedicine.medical_specialtyUterusConnective tissueEndometriummicrotraumaDesmin03 medical and health sciencesEndometrium0302 clinical medicineendometrial–myometrial junctional zoneMetaplasiaMedicineHumansAdenomyosisMyofibroblastscollagen I030219 obstetrics & reproductive medicineurogenital systembusiness.industryMyometriumConnective Tissue Growth FactorObstetrics and Gynecologymedicine.diseaseActinsCTGFmedicine.anatomical_structure030220 oncology & carcinogenesisCase-Control StudiesMyometriumDesminFemalemedicine.symptombusinessReceptors Transforming Growth Factor betaAdenomyosisBiomarkersReproductive sciences (Thousand Oaks, Calif.)
researchProduct

A 20-year follow-up of young women with polycystic ovary syndrome.

2012

OBJECTIVE: To determine whether hormonal, metabolic, and anthropomorphic parameters change over 20 years in women with polycystic ovary syndrome (PCOS). METHODS: One hundred ninety-three women with PCOS, aged 20–25 years, were diagnosed according to Rotterdam criteria, divided into four phenotypes (A–D), and followed at 5-year intervals for 20 years. Androgens, gonadotropins, insulin, glucose, body mass index, waist circumference, and ovarian volume were measured. RESULTS: At diagnosis, 57% had classic features (phenotype A), 9% had classic features without ovarian findings (phenotype B), 26% had the ovulatory phenotype (C), and 7% were nonhyperandrogenic (D). After 10 years, androgens decr…

Adultendocrine system diseasesPhysiologySettore MED/13 - EndocrinologiaBody Mass IndexYoung AdultInsulin resistanceOvarian functionmedicineHumansInsulinTestosteroneYoung adultInsulin bloodbusiness.industryOvaryFollow up studiesObstetrics and GynecologyDehydroepiandrosteroneOrgan SizeLuteinizing HormoneMiddle Agedmedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsPolycystic Ovary Syndrome Ovarian function Ovarian aging Androgens Insulin resistance waist circumferencePhenotypeFemaleFollicle Stimulating HormoneInsulin ResistanceWaist CircumferencebusinessBody mass indexHormoneAnovulationFollow-Up StudiesPolycystic Ovary SyndromeObstetrics and gynecology
researchProduct

Combined use of uterine artery embolization and local methotrexate injection in interstitial ectopic pregnancies with poor prognosis.

2009

Objective To report three cases of interstitial pregnancies treated successfully by combining uterine artery embolization (UAE) and ultrasound-guided local administration of methotrexate (MTX); and to assess the effect of UAE on ovarian reserve by prospectively measuring serum antimullerian hormone (AMH) levels. Design Case report. Setting Departments of obstetrics and gynecology and radiology of a university hospital. Patient(s) Three patients with interstitial pregnancy. Treatment with multiple IM injections of MTX had failed in cases 1 and 3. Case 2 presented high initial serum β-hCG levels (93,563 mIU/mL), suggesting the presence of a substantial amount of trophoblastic tissue. Interven…

Adultendocrine systemPoor prognosismedicine.medical_specialtymedicine.medical_treatmentCombined useUterine artery embolizationObstetrics and gynaecologyPregnancymedicineHumansOvarian reservePregnancybusiness.industryObstetricsObstetrics and GynecologyUterine Artery Embolizationmedicine.diseasePrognosisCombined Modality TherapyPregnancy EctopicMethotrexateReproductive MedicineMethotrexateInterstitial pregnancyFemalebusinessmedicine.drugFertility and sterility
researchProduct

The role of thrombophilia and thyroid autoimmunity in unexplained infertility, implantation failure and recurrent spontaneous abortion.

2007

The role of thrombophilia and thyroid autoimmunity in unexplained infertility (UI), implantation failure (IF) and recurrent spontaneous abortion (RSA) is controversial and poorly understood.From March, 2004 to January, 2007, 119 women were prospectively included: 32 oocyte donors, 31 patients with UI, 26 with IF and 30 with RSA. The IF and RSA groups presented normal preimplantation genetic screening. Protein C, protein S, antithrombin III, lupus anticoagulant, activated protein C resistance (APCR), immunoglobulin M and G anticardiolipin antibodies, homocystine, Factor V Leiden, prothrombin G20210A mutation, methylentetrahydrofolate reductase C677T mutation, thyroid-stimulating hormone (TSH…

Adultendocrine systemmedicine.medical_specialtyAbortion Habitualmedicine.medical_treatmentThyroid GlandAutoimmunityThrombophiliaGastroenterologyIodide PeroxidaseThyroglobulinAntiphospholipid syndromeInternal medicinemedicineFactor V LeidenPrevalenceHumansThrombophiliaEmbryo ImplantationProspective StudiesUnexplained infertilityActivated Protein C ResistanceAutoantibodiesLupus anticoagulantbusiness.industryRehabilitationThyroidObstetrics and Gynecologymedicine.diseaseEndocrinologymedicine.anatomical_structureReproductive MedicineLupus Coagulation InhibitorThyroglobulinFemaleActivated protein C resistancebusinessInfertility FemaleHuman reproduction (Oxford, England)
researchProduct

Pituitary-adrenal responses to ovine corticotropin-releasing factor in polycystic ovary syndrome and in other hyperandrogenic patients.

1990

This study was carried out to further characterize the pituitary-adrenal androgen responses of hyperandrogenic patients with 'classic' polycystic ovary syndrome (PCO) and others who were less distinctive and have been called 'PCO-like'. PCO-like patients differed from PCO only in that serum luteinizing hormone (LH) levels were normal and anovulation was not consistent. Ovine corticotropin-releasing factor (CRF) resulted in normal responses of adrenocorticotropic hormone and cortisol in the two groups when compared to controls, while androstenedione (delta 4A) and dehydroepiandrosterone (DHEA) responses were significantly elevated. There were no differences in the responses of PCO and PCO-li…

Adultendocrine systemmedicine.medical_specialtyHirsutismAdolescentmedicine.drug_classCorticotropin-Releasing HormoneEndocrinology Diabetes and MetabolismDehydroepiandrosteronePituitary-Adrenal SystemAdrenocorticotropic hormoneAnovulationBasal (phylogenetics)EndocrinologyAdrenocorticotropic HormoneInternal medicinemedicineHumansAndrostenedionebusiness.industryAndrostenedioneObstetrics and GynecologyDehydroepiandrosteroneLuteinizing HormoneAndrogenmedicine.diseasePolycystic ovaryeye diseasesHormonesEndocrinologyOvine corticotropin-releasing factorFemalebusinesshuman activitieshormones hormone substitutes and hormone antagonistscirculatory and respiratory physiologyAnovulationPolycystic Ovary SyndromeGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
researchProduct